Switch theme
Sign up to access all valuation multiples
Hebei Changshan Biochemical Pharmaceutical Co Ltd is a biotech high-tech enterprise. It is mainly engaged in the research, development, production, and sale of heparin series products. Some of the company's products are Reserpine sodium, Hyaluronic acid, Heparinoid, Heparin sodium, Tinzaparin sodium, Aspirin enteric-coated tablets, and Yihaitang.
2000
n/a
Last FY Revenue $143M
Last FY EBITDA -$11.2M
$5.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Hebei Changshan achieved revenue of $143M and an EBITDA of -$11.2M.
Hebei Changshan expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hebei Changshan valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $143M | XXX | XXX | XXX |
| Gross Profit | XXX | $23.0M | XXX | XXX | XXX |
| Gross Margin | XXX | 16% | XXX | XXX | XXX |
| EBITDA | XXX | -$11.2M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -8% | XXX | XXX | XXX |
| EBIT | XXX | -$13.4M | XXX | XXX | XXX |
| EBIT Margin | XXX | -9% | XXX | XXX | XXX |
| Net Profit | XXX | -$34.6M | XXX | XXX | XXX |
| Net Margin | XXX | -24% | XXX | XXX | XXX |
| Net Debt | XXX | $182M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Hebei Changshan's stock price is CNY 37 (or $5).
Hebei Changshan has current market cap of CNY 34.4B (or $4.8B), and EV of CNY 36.6B (or $5.1B).
See Hebei Changshan trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.1B | $4.8B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Hebei Changshan has market cap of $4.8B and EV of $5.1B.
Hebei Changshan's trades at 35.5x EV/Revenue multiple, and -454.3x EV/EBITDA.
Equity research analysts estimate Hebei Changshan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hebei Changshan's P/E ratio is not available.
See valuation multiples for Hebei Changshan and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.8B | XXX | $4.8B | XXX | XXX | XXX |
| EV (current) | $5.1B | XXX | $5.1B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 35.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -454.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -378.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -137.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -199.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHebei Changshan's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Hebei Changshan's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hebei Changshan's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hebei Changshan and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -8% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hebei Changshan acquired XXX companies to date.
Last acquisition by Hebei Changshan was XXXXXXXX, XXXXX XXXXX XXXXXX . Hebei Changshan acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hebei Changshan founded? | Hebei Changshan was founded in 2000. |
| Where is Hebei Changshan headquartered? | Hebei Changshan is headquartered in China. |
| Is Hebei Changshan publicy listed? | Yes, Hebei Changshan is a public company listed on SHE. |
| What is the stock symbol of Hebei Changshan? | Hebei Changshan trades under 300255 ticker. |
| When did Hebei Changshan go public? | Hebei Changshan went public in 2011. |
| Who are competitors of Hebei Changshan? | Similar companies to Hebei Changshan include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Hebei Changshan? | Hebei Changshan's current market cap is $4.8B |
| Is Hebei Changshan profitable? | Yes, Hebei Changshan is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
